Literature DB >> 15589579

Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.

Cheng-Han Lee1, Hui Xue, Margaret Sutcliffe, Peter W Gout, David G Huntsman, Dianne M Miller, C Blake Gilks, Y Z Wang.   

Abstract

OBJECTIVE: To evaluate subrenal capsule xenografting of primary ovarian tumor tissues in mice for development of new ovarian cancer models.
METHODS: Pieces (1 x 3 x 3 mm) of ovarian tumor specimens from patients were meticulously grafted under renal capsules of female NOD/SCID mice within 2 h of surgical removal. Tumor types included papillary serous adenocarcinomas, borderline and benign mucinous cystadenomas, granulosa cell tumors, a serous borderline tumor and a grade 3 mixed surface epithelial tumor of transitional and undifferentiated types. After 1-2 months, grafts were retrieved for comparison with original tissues. Hematoxylin and eosin (H&E) and immunohistochemical staining was carried out using tissue micro-arrays and CEA, B72.3, WT-1, OC125, keratin, inhibin, CK7, CK20, Cam5.2, and MIB-1 as markers.
RESULTS: Tumor tissue engraftment rate was > 95%. Comparison of donor and post-graft tissues showed highly similar histopathological features; 91 +/- 5% concordance in immunostaining indicated major preservation of immunophenotypes in the xenografts for 30-60 days. There was a small, but significant, increase in MIB-1 proliferative index in xenografts compared to original specimens.
CONCLUSIONS: Subrenal capsule xenografts of primary human ovarian tumors in SCID mice can retain major histopathological and immunohistochemical characteristics of the original tissues. The achievable, consistently high engraftment rate allows use of such xenografts as tools for studying a wide range of ovarian tumors, including granulosa cell tumors and benign, borderline, and malignant surface epithelial neoplasms. Potential applications include preclinical testing of patients' tumor responses to various chemotherapeutic regimens, evaluation of novel therapeutic agents, analysis of tumor progression at cellular and molecular levels, and identification of new therapeutic targets.

Entities:  

Mesh:

Year:  2005        PMID: 15589579     DOI: 10.1016/j.ygyno.2004.09.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  39 in total

1.  Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Authors:  S John Weroha; Marc A Becker; Sergio Enderica-Gonzalez; Sean C Harrington; Ann L Oberg; Matthew J Maurer; Sarah E Perkins; Mariam AlHilli; Kristina A Butler; Sarah McKinstry; Stephanie Fink; Robert B Jenkins; Xiaonan Hou; Kimberly R Kalli; Karin M Goodman; Jann N Sarkaria; Beth Y Karlan; Amanika Kumar; Scott H Kaufmann; Lynn C Hartmann; Paul Haluska
Journal:  Clin Cancer Res       Date:  2014-01-07       Impact factor: 12.531

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

Review 3.  Patient-derived xenograft models in gynecologic malignancies.

Authors:  Clare L Scott; Helen J Mackay; Paul Haluska
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

4.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

5.  Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts.

Authors:  Monique D Topp; Lynne Hartley; Michele Cook; Valerie Heong; Emma Boehm; Lauren McShane; Jan Pyman; Orla McNally; Sumitra Ananda; Marisol Harrell; Dariush Etemadmoghadam; Laura Galletta; Kathryn Alsop; Gillian Mitchell; Stephen B Fox; Jeffrey B Kerr; Karla J Hutt; Scott H Kaufmann; Elizabeth M Swisher; David D Bowtell; Matthew J Wakefield; Clare L Scott
Journal:  Mol Oncol       Date:  2014-01-24       Impact factor: 6.603

6.  A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.

Authors:  Erin George; Hyoung Kim; Clemens Krepler; Brandon Wenz; Mehran Makvandi; Janos L Tanyi; Eric Brown; Rugang Zhang; Patricia Brafford; Stephanie Jean; Robert H Mach; Yiling Lu; Gordon B Mills; Meenhard Herlyn; Mark Morgan; Xiaochen Zhang; Robert Soslow; Ronny Drapkin; Neil Johnson; Ying Zheng; George Cotsarelis; Katherine L Nathanson; Fiona Simpkins
Journal:  JCI Insight       Date:  2017-01-12

Review 7.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

8.  Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Authors:  Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

9.  A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro.

Authors:  Vincent C Daniel; Luigi Marchionni; Jared S Hierman; Jonathan T Rhodes; Wendy L Devereux; Charles M Rudin; Rex Yung; Giovanni Parmigiani; Marion Dorsch; Craig D Peacock; D Neil Watkins
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

10.  Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.

Authors:  Bjoern Chapuy; Hongwei Cheng; Akira Watahiki; Matthew D Ducar; Yuxiang Tan; Linfeng Chen; Margaretha G M Roemer; Jing Ouyang; Amanda L Christie; Liye Zhang; Daniel Gusenleitner; Ryan P Abo; Pedro Farinha; Frederike von Bonin; Aaron R Thorner; Heather H Sun; Randy D Gascoyne; Geraldine S Pinkus; Paul van Hummelen; Gerald G Wulf; Jon C Aster; David M Weinstock; Stefano Monti; Scott J Rodig; Yuzhuo Wang; Margaret A Shipp
Journal:  Blood       Date:  2016-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.